Literature DB >> 8194708

Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2.

K Michitaka1, M Durazzo, H L Tillmann, D Walker, T Philipp, M P Manns.   

Abstract

BACKGROUND/AIMS: Hepatitis C virus (HCV) RNA is detectable in a proportion of patients with autoimmune hepatitis type 2, which is characterized by liver-kidney microsomal antibodies (LKM). Therefore, the genotype and sequence of HCV were studied in these patients.
METHODS: Sera from 43 LKM-positive and anti-HCV-positive patients (15 from Germany and 28 from Italy) and 82 LKM-negative and anti-HCV-positive patients (57 from Germany and 25 from Italy) were examined.
RESULTS: Genotyping revealed that the rate of genotype III HCV according to Okamoto's classification in patients with LKM antibody-positive autoimmune hepatitis type 2 was higher than in LKM-negative patients (22.0% vs. 2.4%; P < 0.05). This was because of an increase of genotype III in our patients from Italy. No HCV mutations were found that show a closer sequence homology to cytochrome P450IID6, the major LKM-1 antigen. Deletions in the envelope and nonstructural region 5 were found.
CONCLUSIONS: Because a specific HCV sequence is not associated with the induction of LKM-1 autoantibodies, future research must focus on host factors and possibly additional environmental factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194708     DOI: 10.1016/0016-5085(94)90417-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Autoimmunity in liver diseases.

Authors:  C P Strassburg; P Obermayer-Straub; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

3.  Successful treatment with corticosteroid and lamivudine for autoimmune hepatitis in a patient with asymptomatic HBV infection.

Authors:  Reiichiro Kuwahara; Hiroki Saitsu; Mitsuhiko Abe; Akio Takata; Kazuo Tanaka; Teruko Hino; Tatsuya Ide; Ryoko Kuromatsu; Ken Tanikawa; Masayoshi Kage; Ryukichi Kumashiro; Michio Sata
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

Review 4.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 6.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis.

Authors:  H Miyakawa; E Kitazawa; K Abe; N Kawaguchi; H Fuzikawa; K Kikuchi; M Kako; T Komatsu; N Hayashi; K Kiyosawa
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

8.  Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.

Authors:  B Wesche; E Jaeckel; C Trautwein; H Wedemeyer; A Falorni; H Frank; A von zur Mühlen; M P Manns; G Brabant
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  Kidney transplantation in hepatitis B surface antigen carriers.

Authors:  V Kliem; B Ringe; K Holhorst; U Frei
Journal:  Clin Investig       Date:  1994-12

Review 10.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.